Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-22
2011-03-22
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120
Reexamination Certificate
active
07910318
ABSTRACT:
A method comprising: providing a biological sample from a subject (subject sample); and detecting the expression level of each of the markers FGF-2 and CA125 in the subject sample. A kit comprising means for detection of an expression level of each of markers CA125 and FGF-2 in a biological sample from a subject (subject sample), and instructions to use said markers in a method of the present invention.
REFERENCES:
patent: 2004/0005563 (2004-01-01), Mack et al.
patent: 2004/0010121 (2004-01-01), Birse et al.
patent: 2005/0059013 (2005-03-01), Chan et al.
patent: 2005/0069963 (2005-03-01), Lokshin et al.
patent: WO2005/016126 (2005-02-01), None
patent: WO/2005/083440 (2005-09-01), None
Lu et al (Clinical Cancer Research, May 2004, 10:3291-3300).
Le Page et al (Int. J. Cancer, 2006, 118:1750-1758).
Ileri et al (Nephrol. Dial. Transplant, 2000, 15(9):A234).
McIntosh et al (Gynecologic Oncology, 2004, 95:9-15).
Barton et al (Clinical Cancer Research, 1997, 3:1579-1586).
Akahiro et al (Int J Clin Oncol, 2004, 9(1): 42-46).
Internet Citation, XP002232760, “GeneChip Human Genome U133 Set”, Retrieved on Feb. 26, 2003.
Kaku et al., “Histological classification of ovarian cancer”, Med Electron Microsc, (2003), vol. 36:9-17.
Kim et al., “Osteopontin as a potential diagnostic biomarker for ovarian cancer”, Jama, (2002) vol. 287: 1671-1679.
Kruk et al., “A simplified method to culture human ovarian surface epithelium”, Lab. Invest., (1990) vol. 63: 132-136.
Le Page et al., “Signature of a silent killer: expression profiling in epithelial ovarian cancer”, Expert Rev. Mol. Diagn. vol. 4 No. 2: 157-167.
Le Page et al., “From gene profiling to diagnostic markers: IL-18 and FGF-2 complement . . . ”, Int. J. Cancer (2006), vol. 118: 1750-1758.
Lounis et al., “Primary cultures of normal and tumoral human ovarian epithelium: A powerful tool for basic molecular studies”, Exp. Cell Res., (1994), vol. 215: 303-309.
Lu et al., Selection of potential markers for epithelial ovarian cancer . . . , Clinical Cancer Research, (2004), vol. 10: 3291-3300.
McIntosh et al., “Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma”, Gynecol Oncol, (2004) vol. 95: 9-15.
Meyer et al., “Role of tumour markers in monitoring epithelial ovarian cancer”, Br J Cancer, (2000), vol. 82: 1535-1538.
Modugno F. “Ovarian cancer and high-risk women-implications for prevention, screening, and early detection”, Gynecol Oncol, (2003), vol. 91: 15-31.
Mok et al., “Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology”, J Natl Cancer Inst, (2001) vol. 93: 1458-1464.
Ouellet et al., “Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling”, Oncogene, vol. 24: 4672-4687.
Pfaffl M. W., “A new mathematical model for relative quantification in real-time RT-PCR”, Nucleic Acids Res, (2001) vol. 29: 2002-2007.
Rosen et al., “Potential markers that complement expression of CA125 in epithelial ovarian cancer”, Gynecologic Oncology, Academic Press, (2005), vol. 99, No. 2: 267-277.
Tamayo et al., “Interpreting patterns of gene expression with self-organizing maps: methods and application . . . ”, Proc Natl Acad Sci, (1999), vol. 96: 2907-2912.
Woolas et al., “Combinations of multiple serum markers are superior to individual assays for discriminating malignant . . . ”, Gynecol Oncol, (1995), vol. 59: 111-116.
Woolas et al., “Elevation of multiple serum markers in patients with stage I ovarian cancer”, J Natl Cancer Inst, (1993) vol. 85: 1748-1751.
IPRP PCT/CA2006/001536, Mar. 22, 2007, Val-Chum, S.E.C. et al.
ISR PCT/CA2006/001536, Jan. 8, 2007.
EP06790705 Supp. EP search, Sep. 26, 2008, Val-Chum, S.E.C. et al.
Agarwal et al., “Familial recurrent molar pregnancy: a case report”, Acta Obstet Gynecol Scand, (2004), vol. 83: 213-4.
Akahira et al., “Impact of serum interleukin-18 level as a prognostic indicator in patients . . . ”, Int. Journal of Clinical Oncology, (2004), vol. 9: 942-946.
Auersperg et al., “Ovarian surface epithelium: biology, endocrinology, and pathology”, Endocr Rev., (2001), vol. 22: 255-288.
Bast et al., “Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen”, Am J Obstet Gynecol, (1984), vol. 149: 553-559.
Chan Éric, “Integrating Transcriptomics and Proteomics”, Genomics and Proteomics, (2006), pp. 1-6.
Chuaqui et al., “Histopathology and molecular biology of ovarian epithelial tumors”, Ann Diagn Pathol, (1998), vol. 2: 195-207.
Crispens M. A., “Borderline ovarian tumours: a review of the recent literature”, Curr Opin Obstet Gynecol, (2003), vol. 15: 39-43.
De Cecco et al., “Gene expression profiling of advanced ovarian cancer . . . ” , Oncogene, (2004), vol. 23: 8171-8183.
Hellstrom et al. “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma”, Cancer Res, (2003), vol. 63: 3695-3700.
Ileri et al., The predictive value of cancer antigen 125 (CA125), collagen III . . . , Nephrology Dialysis Transplantation, (2000) vol. 15 No. 9: A234.
Bast et al., “Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen”, Am. J. Obstet. Gynecol. (1984), vol. 149: 553-559.
Gaggero et al., “A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing”, Oncogene, (2004), vol. 23: 7552-7560.
Yurkovestsky et al. “Development of a Multimarker Assay for Early Detection of Ovarian Cancer”, Journal of Clinical Oncology, (2010), vol. 28(13): 2159-2166.
Hudson Thomas
LePage Cecile
Mes-Masson Anne-Marie
Provencher Diane
Tonin Patricia
Aeder Sean E
Gauvreau Julie
Goudreau Gage Dubuc
The Royal Institution for the Advancement of Learning/McGill Uni
Val-Chum, S.E.C.
LandOfFree
Methods of diagnosing ovarian cancer and kits therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing ovarian cancer and kits therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing ovarian cancer and kits therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683487